TB Research

Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1

Priya Ragunathan, Thomas Dick, Gerhard Grüber

Antimicrobial Agents and Chemotherapy · 2022-04

Abstract

New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti-M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.

MeSH terms

  • Clofazimine
  • Mycobacterium abscessus
  • ATP synthase
  • Rifabutin
  • Microbiology
  • Mycobacterium tuberculosis
  • Bedaquiline
  • Amikacin
  • Chemistry
  • Biology
  • Pharmacology
  • Mycobacterium
  • Antibiotics